BridgeBio Pharma, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BBIO Nasdaq 2830 bridgebio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BridgeBio Pharma, Inc.

BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference - Mar 4th, 2026 5:30 am
BridgeBio Pharma (BBIO) Achieves Record 2025 Revenue Driven by Attruby Commercial Success - Mar 3rd, 2026 12:21 am
Is BridgeBio Pharma (BBIO) Attractive After Recent Pullback And Late Stage Pipeline Progress? - Mar 2nd, 2026 2:12 am
BridgeBio Pharma Inc (BBIO) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Feb 24th, 2026 10:03 pm
BridgeBio Pharma, Inc. Q4 2025 Earnings Call Summary - Feb 24th, 2026 6:03 pm
BridgeBio Pharma (BBIO) Reports Q4 Loss, Beats Revenue Estimates - Feb 24th, 2026 5:30 pm
BridgeBio Pharma Q4 Earnings Call Highlights - Feb 24th, 2026 4:26 pm
BridgeBio Pharma: Q4 Earnings Snapshot - Feb 24th, 2026 2:24 pm
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates - Feb 24th, 2026 2:01 pm
BridgeBio to Participate in March Investor Conferences - Feb 23rd, 2026 5:30 am
BridgeBio Pharma (BBIO) Valuation Check After Strong Phase 3 PROPEL 3 Results In Achondroplasia - Feb 18th, 2026 3:14 pm
BoFA Notes BridgeBio Pharma, Inc. (BBIO)’s Upcoming Q4 Earnings May Have Limited Market Impact - Feb 17th, 2026 10:45 pm
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Feb 17th, 2026 4:22 pm
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition - Feb 17th, 2026 11:07 am
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough - Feb 17th, 2026 10:58 am
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge - Feb 17th, 2026 10:52 am
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q4 Earnings Expected to Decline - Feb 17th, 2026 8:00 am
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET - Feb 17th, 2026 5:30 am
Tyra Biosciences price target raised to $53 from $37 at Wedbush - Feb 14th, 2026 7:05 am
Why BridgeBio Pharma (BBIO) Is Up 10.6% After Breakthrough Phase 3 Infigratinib Data In Achondroplasia - Feb 13th, 2026 8:21 pm